Theophylline as `add-on' therapy to cetirizine in patients with chronic idiopathic urticaria - A randomized, double-blind, placebo-controlled pilot study
δείτε την πρωτότυπη σελίδα τεκμηρίου στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*
Theophylline as `add-on' therapy to cetirizine in patients with chronic
idiopathic urticaria - A randomized, double-blind, placebo-controlled
pilot study
Kalogeromitros, D
Kempuraj, D
Katsarou-Katsari, A
Makris, M
and Gregoriou, S
Papaliodis, D
Theoharides, TC
Background: Chronic urticaria is a prevalent condition associated with
substantial disability. Its pathogenesis is not clearly understood and
is divided into autoimmune and chronic idiopathic urticaria (CIU). We
investigated if the non-specific phosphodiesterase inhibitor
theophylline could provide additional benefit to the histamine-1
receptor (H-1R) antagonist cetirizine in CIU. Methods: This was a
double-blind, placebo-controlled, parallel study. Patients were
randomized to receive either cetirizine and theophylline (200 mg twice
daily; group A, 67 subjects) or cetirizine and placebo for 6 months
(group B, 67 subjects). Group A patients took theophylline for 6 more
months. Response was assessed by visual analog scale ( VAS) and
treatment effectiveness score (TES). Blood theophylline levels were also
determined at visit t = 1 and t = 7. Results: The study was completed by
54 of the 67 patients (80.6%) in group A and 51 of the 67 patients
(76.1%) in group B. The physician VAS values for group A were lower
after t = 3, while the patient VAS values were decreased after t = 2.
The physician and patient TES values in group A were statistically
higher (p < 0.05) at all time points except for t = 1. At least 1 month
of theophylline addition was necessary to obtain statistically
significant benefit over cetirizine, and reducing theophylline by 50%
during phase 2 did not alter this benefit. Pruritus values were reduced,
but not statistically significant. Conclusions: Addition of theophylline
to conventional H-1R antagonists was well tolerated without any adverse
effects and provided considerable additional benefit in the management
of CIU. Copyright (C) 2006 S. Karger AG, Basel.
(EN)
*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.
Βοηθείστε μας να κάνουμε καλύτερο το OpenArchives.gr.
Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών
